Axonis is a technology company.
Axonis has raised $5.0M across 1 funding round.
Axonis has raised $5.0M in total across 1 funding round.
Axonis has raised $5.0M in total across 1 funding round.
Axonis's investors include Stuart Peterson, Vasudev Bailey, BoxOne Ventures, Social Capital, Unless.
Axonis Therapeutics is a biotechnology company developing first-in-class neuron-reviving therapies for incurable neurological disorders by targeting the KCC2 protein to restore excitation/inhibition balance in the brain. It focuses on conditions like epilepsy, chronic pain, seizures, motor/sensory issues, and neurodevelopmental disorders such as SYNGAP1 and Rett syndrome, serving patients and the healthcare industry through oral KCC2 potentiator drugs.[1][2] Its lead candidate, AXN-027, is in first-in-human clinical trials, supported by a proprietary discovery engine from academic origins and a $115 million Series A round in October 2024, signaling strong growth momentum amid rising demand for CNS therapies.[2]
Axonis Therapeutics emerged from scientific breakthroughs at Boston Children’s Hospital, Harvard University, and Laval University, with foundational work on KCC2 expression in neurons for pediatric brain disorders.[1][2] Founded around 2019 (with roots tracing to 2008 per some records), it was co-founded by Chief Scientific Founder Dr. Shane Hegarty, PhD, whose research identified small-molecule drugs stimulating KCC2, showing promise in human neuron and mouse models of Rett syndrome.[1] Early traction included proof-of-concept studies funded by the SynGAP Research Fund for SYNGAP1 syndrome models, leading to emergence from stealth with substantial venture backing and advancement of AXN-027 into clinical trials.[1][2]
(Note: Distinct from unrelated AI/security firms like Axonius or a federated AI startup using the name, based on mismatched profiles.)[3][4][5]
Axonis rides the wave of precision neurology and neuroregeneration, targeting synaptic inhibition deficits amid a $50B+ CNS therapeutics market strained by inadequate epilepsy/pain treatments (affecting millions globally).[1][2] Timing aligns with advances in translational biotech from academia, AI-aided discovery, and post-pandemic investor focus on high-impact healthcare, where KCC2 modulation fills gaps in gene therapy or symptomatic drugs.[1][2] It influences the ecosystem by validating rare neurological models (e.g., SYNGAP1, Rett), potentially accelerating similar neuron-focused startups and partnerships with Big Pharma for scalable oral therapies.[1]
Axonis is poised for Phase II trials with AXN-027, expanding its pipeline amid surging neuro-biotech funding and AI-driven efficiency. Trends like synaptic repair and oral CNS penetration will propel it, potentially evolving into a leader in inhibition-restoring meds if data confirms preclinical rescues in human models. Watch for partnerships or Series B to scale global trials, amplifying its role from stealth innovator to ecosystem shaper in neurodegeneration.
Axonis has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $5.0M Seed | Stuart Peterson, Vasudev Bailey, BoxOne Ventures, Social Capital, Unless |